Supernus Pharmaceuticals, Inc. $SUPN Shares Acquired by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH increased its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 28.4% in the third quarter, Holdings Channel.com reports. The institutional investor owned 109,836 shares of the specialty pharmaceutical company’s stock after acquiring an additional 24,302 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Supernus Pharmaceuticals were worth $5,249,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently added to or reduced their stakes in the stock. Royal Bank of Canada boosted its holdings in shares of Supernus Pharmaceuticals by 68.1% during the first quarter. Royal Bank of Canada now owns 11,669 shares of the specialty pharmaceutical company’s stock valued at $382,000 after acquiring an additional 4,729 shares during the period. AQR Capital Management LLC lifted its position in Supernus Pharmaceuticals by 35.2% in the 1st quarter. AQR Capital Management LLC now owns 85,224 shares of the specialty pharmaceutical company’s stock valued at $2,791,000 after purchasing an additional 22,182 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Supernus Pharmaceuticals by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,860 shares of the specialty pharmaceutical company’s stock valued at $978,000 after purchasing an additional 1,297 shares during the last quarter. Millennium Management LLC boosted its stake in Supernus Pharmaceuticals by 370.5% during the 1st quarter. Millennium Management LLC now owns 143,356 shares of the specialty pharmaceutical company’s stock valued at $4,695,000 after purchasing an additional 112,886 shares during the period. Finally, Empowered Funds LLC grew its position in Supernus Pharmaceuticals by 16.0% in the 1st quarter. Empowered Funds LLC now owns 48,045 shares of the specialty pharmaceutical company’s stock worth $1,573,000 after purchasing an additional 6,619 shares during the last quarter.

Insider Transactions at Supernus Pharmaceuticals

In related news, VP Padmanabh P. Bhatt sold 710 shares of the business’s stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $44.44, for a total value of $31,552.40. Following the sale, the vice president directly owned 14,508 shares in the company, valued at $644,735.52. The trade was a 4.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Frank Mottola sold 20,000 shares of the stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $50.41, for a total transaction of $1,008,200.00. Following the sale, the senior vice president directly owned 15,496 shares of the company’s stock, valued at approximately $781,153.36. This represents a 56.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 8.80% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on SUPN shares. Piper Sandler upgraded Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $40.00 to $65.00 in a research report on Thursday, October 9th. TD Cowen lifted their target price on Supernus Pharmaceuticals from $45.00 to $60.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. Bank of America began coverage on Supernus Pharmaceuticals in a research note on Wednesday, October 29th. They issued a “buy” rating and a $65.00 price target for the company. Stifel Nicolaus raised their price target on Supernus Pharmaceuticals from $50.00 to $55.00 and gave the company a “hold” rating in a report on Friday, December 19th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $61.60.

Supernus Pharmaceuticals Stock Performance

Shares of SUPN stock opened at $49.16 on Tuesday. Supernus Pharmaceuticals, Inc. has a 1 year low of $29.16 and a 1 year high of $57.65. The business’s fifty day moving average is $48.47 and its 200-day moving average is $45.84. The stock has a market cap of $2.82 billion, a PE ratio of -144.58, a price-to-earnings-growth ratio of 0.42 and a beta of 0.67.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Tuesday, November 4th. The specialty pharmaceutical company reported $0.46 earnings per share for the quarter, missing the consensus estimate of $0.82 by ($0.36). The firm had revenue of $170.00 million during the quarter, compared to analyst estimates of $175.82 million. Supernus Pharmaceuticals had a negative net margin of 2.81% and a positive return on equity of 11.51%. The company’s quarterly revenue was up 9.3% compared to the same quarter last year. During the same quarter last year, the company earned $0.69 EPS. Equities research analysts predict that Supernus Pharmaceuticals, Inc. will post 2.38 earnings per share for the current year.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained?release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended?release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended?release capsules), approved for the treatment of attention?deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.